Video Experimental Relacionado
Updated: Jul 6, 2026
06:48
The MUB40 Peptide for Use in Detecting Neutrophil-Mediated Inflammation Events
Published on: January 7, 2019
La eritropoietina y la agregación plaquetaria espontánea en pacientes en hemodiálisis
J E Taylor1, I S Henderson, W K Stewart
1Renal Unit, Ninewells Hospital and Medical School, Dundee, UK.
Lancet (London, England)
|November 30, 1991
Resumen
El tratamiento con eritropoietina aumenta la agregación plaquetaria en pacientes en diálisis, aumentando el riesgo de trombosis. La aspirina revirtió este efecto, lo que sugiere un vínculo entre la eritropoietina, la función plaquetaria y la coagulación.
Área de la Ciencia:
- Nefrología Nefrología.
- Hematología Hematología.
- Farmacología Farmacología.
Sus antecedentes:
- Los pacientes sometidos a hemodiálisis a menudo experimentan complicaciones relacionadas con la anemia.
- La eritropoietina es un tratamiento común para la anemia en la enfermedad renal crónica.
- Las anomalías de la función plaquetaria se observan en pacientes urémicos.
Objetivo del estudio:
- Para investigar el efecto de la eritropoyetina en la agregación plaquetaria en pacientes en hemodiálisis.
- Para determinar si la eritropoyetina influye en la agregación plaquetaria espontánea.
- Para evaluar el impacto de la aspirina en los cambios en las plaquetas inducidos por la eritropoyetina.
Principales métodos:
- Estudió a 15 pacientes en hemodiálisis de mantenimiento.
- Se midió la agregación plaquetaria espontánea en sangre entera in vitro.
- Niveles de agregación comparados durante el tratamiento con eritropoyetina con controles no urémicos.
- Se administró 300 mg de aspirina al día para evaluar su efecto.
Principales resultados:
- La eritropoietina aumentó significativamente la agregación plaquetaria espontánea.
- La agregación plaquetaria en los pacientes tratados fue mayor que en los controles.
- La administración diaria de aspirina revirtió la hiperagregabilidad inducida por la eritropoyetina.
- Los efectos observados fueron significativos, reversibles y reproducibles.
Conclusiones:
- La eritropoietina puede mejorar la función plaquetaria, aumentando potencialmente el riesgo de trombosis en pacientes en hemodiálisis.
- La aspirina contrarrestó eficazmente la hiperagregabilidad plaquetaria inducida por la eritropoyetina.
- Esto sugiere un mecanismo que involucra la función plaquetaria a través del cual la eritropoyetina podría promover la trombosis.
Videos de Conceptos Relacionados
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:24Hemoglobin
Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
01:22Lifecycle of Erythrocytes
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:10Blood Typing
Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...